Furthermore, Ning et al. [29] suggested that PLS3 rs6643869 SNP could serve as stage-specific molecular predictor of tumor recurrence in stages II/III CRC patients as well as a potential therapeutic target. The gene discussed is PLS3; the disease is neoplasm.